Oral Wegovy Approved: New Pill Offers Hope for Obesity Treatment

• US FDA approved Novo Nordisk's oral Wegovy (semaglutide) for obesity treatment, offering a daily pill alternative to injections.
• The GLP-1 drug mimics a natural hormone, reducing appetite, slowing digestion, and signaling fullness to aid weight loss.
• Clinical trials showed oral Wegovy led to an average 13.6% weight loss over 15 months, comparable to injectable versions.
• Expected to be available in weeks, the pill aims to increase access and potentially lower costs for obesity treatment.
• Obesity is a major health issue globally, including in the US (100 million affected) and India (140 million, 1/4 adults).

Why It Matters: Oral Wegovy's FDA approval offers a new, accessible option for obesity management, potentially transforming treatment.